BPTSY (Biophytis) Moat Score: 2/10 (As of Jul. 01, 2026)


BPTSY Biophytis SA BPTSY
18 GF Score
Price $0.25
! 5 Warning Signs
View Full Analysis

What is Biophytis Moat Score?

Biophytis BPTSY 18 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates BPTSY with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 1,400 Biotechnology companies, Biophytis ranks better than 58.07% on this metric.

Biophytis has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Biophytis has No Moat: Biophytis SA has very weak competitive advantages with limited intellectual property and no significant market share. It faces intense competition in the biotech sector and lacks customer loyalty or cost advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Biophytis might have No Moat - Very weak/transient advantages.

Biophytis  (OTCPK:BPTSY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Biophytis Moat Score Related Terms

BPTSY vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Biophytis's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biophytis Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biophytis's Moat Score distribution charts can be found below:

* The bar in red indicates where Biophytis's Moat Score falls into.


BPTSY
18GF Score
Biophytis SA BPTSY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Biophytis (BPTSY) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Biophytis ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Biophytis' Moat Score too high?
Biophytis' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Biophytis' value of 2 is 0% at this industry median. Based on the distribution chart, Biophytis ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biophytis has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biophytis ranks #587 out of 1400 companies for Moat Score. This puts Biophytis in the upper half of its industry. The industry median Moat Score is 2.00. Biophytis' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biophytis's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biophytis's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Biophytis' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Biophytis (BPTSY), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
18GF Score

Get the complete analysis for BPTSY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price